Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults
Phase of Trial: Phase IV
Latest Information Update: 22 Nov 2018
Price : $35 *
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Acronyms ORKAJA
- 13 Nov 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2018.
- 13 Nov 2018 Planned primary completion date changed from 1 Sep 2020 to 1 Dec 2018.
- 13 Nov 2018 Status changed from not yet recruiting to recruiting.